Quadrant Capital Group LLC lifted its position in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 83.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,084 shares of the company’s stock after acquiring an additional 10,942 shares during the quarter. Quadrant Capital Group LLC’s holdings in Takeda Pharmaceutical were worth $476,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Hudock Capital Group LLC bought a new stake in shares of Takeda Pharmaceutical during the first quarter worth $26,000. Shine Investment Advisory Services Inc. acquired a new stake in shares of Takeda Pharmaceutical during the first quarter worth $28,000. Contravisory Investment Management Inc. acquired a new stake in shares of Takeda Pharmaceutical during the first quarter worth $28,000. First Hawaiian Bank acquired a new stake in shares of Takeda Pharmaceutical during the first quarter worth $35,000. Finally, Dubuque Bank & Trust Co. acquired a new stake in shares of Takeda Pharmaceutical during the first quarter worth $41,000. Institutional investors own 4.42% of the company’s stock.
Shares of Takeda Pharmaceutical stock traded down $0.44 during trading on Wednesday, reaching $17.48. 3,133,500 shares of the company were exchanged, compared to its average volume of 3,698,572. The company has a quick ratio of 2.81, a current ratio of 1.22 and a debt-to-equity ratio of 0.92. Takeda Pharmaceutical Co Ltd has a twelve month low of $15.50 and a twelve month high of $21.95. The stock has a market cap of $27.29 billion, a PE ratio of 16.34 and a beta of 0.66.
A number of brokerages recently commented on TAK. Zacks Investment Research raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Wednesday, March 13th. ValuEngine cut Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. Finally, Goldman Sachs Group reaffirmed a “buy” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, March 19th.
TRADEMARK VIOLATION WARNING: “Quadrant Capital Group LLC Has $476,000 Position in Takeda Pharmaceutical Co Ltd (NYSE:TAK)” was first published by Sundance Herald and is owned by of Sundance Herald. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://sundanceherald.com/2019/05/22/takeda-pharmaceutical-co-ltd-tak-shares-bought-by-quadrant-capital-group-llc.html.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Article: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.